460 related articles for article (PubMed ID: 25035124)
21. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
Allard B; Turcotte M; Stagg J
Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
[TBL] [Abstract][Full Text] [Related]
22. CD73 and adenosine generation in the creation of regulatory microenvironments.
Regateiro FS; Cobbold SP; Waldmann H
Clin Exp Immunol; 2013 Jan; 171(1):1-7. PubMed ID: 23199317
[TBL] [Abstract][Full Text] [Related]
23. Measurement of CD73 enzymatic activity using luminescence-based and colorimetric assays.
Allard B; Cousineau I; Spring K; Stagg J
Methods Enzymol; 2019; 629():269-289. PubMed ID: 31727245
[TBL] [Abstract][Full Text] [Related]
24. CD39 and CD73 in immunity and inflammation.
Antonioli L; Pacher P; Vizi ES; Haskó G
Trends Mol Med; 2013 Jun; 19(6):355-67. PubMed ID: 23601906
[TBL] [Abstract][Full Text] [Related]
25. CD39-mediated effect of human bone marrow-derived mesenchymal stem cells on the human Th17 cell function.
Lee JJ; Jeong HJ; Kim MK; Wee WR; Lee WW; Kim SU; Sung C; Yang YH
Purinergic Signal; 2014; 10(2):357-65. PubMed ID: 24043462
[TBL] [Abstract][Full Text] [Related]
26. Adenosine pathway and cancer: where do we go from here?
Antonioli L; Haskó G; Fornai M; Colucci R; Blandizzi C
Expert Opin Ther Targets; 2014 Sep; 18(9):973-7. PubMed ID: 24958495
[TBL] [Abstract][Full Text] [Related]
27. Targeting Metabolism of Extracellular Nucleotides via Inhibition of Ectonucleotidases CD73 and CD39.
Jeffrey JL; Lawson KV; Powers JP
J Med Chem; 2020 Nov; 63(22):13444-13465. PubMed ID: 32786396
[TBL] [Abstract][Full Text] [Related]
28. Targeting CD73 to augment cancer immunotherapy.
Roh M; Wainwright DA; Wu JD; Wan Y; Zhang B
Curr Opin Pharmacol; 2020 Aug; 53():66-76. PubMed ID: 32777746
[TBL] [Abstract][Full Text] [Related]
29. CD73 (Cluster of Differentiation 73) and the Differences Between Mice and Humans.
Joolharzadeh P; St Hilaire C
Arterioscler Thromb Vasc Biol; 2019 Mar; 39(3):339-348. PubMed ID: 30676071
[TBL] [Abstract][Full Text] [Related]
30. Fructose 1,6-bisphosphate, a high-energy intermediate of glycolysis, attenuates experimental arthritis by activating anti-inflammatory adenosinergic pathway.
Veras FP; Peres RS; Saraiva AL; Pinto LG; Louzada-Junior P; Cunha TM; Paschoal JA; Cunha FQ; Alves-Filho JC
Sci Rep; 2015 Oct; 5():15171. PubMed ID: 26478088
[TBL] [Abstract][Full Text] [Related]
31. ATP and adenosine: Role in the immunopathogenesis of rheumatoid arthritis.
da Silva JLG; Passos DF; Bernardes VM; Leal DBR
Immunol Lett; 2019 Oct; 214():55-64. PubMed ID: 31479688
[TBL] [Abstract][Full Text] [Related]
32. Adenosine and adenosine receptors in the immunopathogenesis and treatment of cancer.
Kazemi MH; Raoofi Mohseni S; Hojjat-Farsangi M; Anvari E; Ghalamfarsa G; Mohammadi H; Jadidi-Niaragh F
J Cell Physiol; 2018 Mar; 233(3):2032-2057. PubMed ID: 28233320
[TBL] [Abstract][Full Text] [Related]
33. CD39/CD73 and the imbalance of Th17 cells and regulatory T cells in allergic asthma.
Wang LL; Tang HP; Shi GC; Wan HY; Tang W; Hou XX; Pan LN; Shi BY; Tao LQ
Mol Med Rep; 2013 Nov; 8(5):1432-8. PubMed ID: 24065069
[TBL] [Abstract][Full Text] [Related]
34. CD73 Promotes Resistance to HER2/ErbB2 Antibody Therapy.
Turcotte M; Allard D; Mittal D; Bareche Y; Buisseret L; José V; Pommey S; Delisle V; Loi S; Joensuu H; Kellokumpu-Lehtinen PL; Sotiriou C; Smyth MJ; Stagg J
Cancer Res; 2017 Oct; 77(20):5652-5663. PubMed ID: 28855210
[TBL] [Abstract][Full Text] [Related]
35. The therapeutic potential of targeting CD73 and CD73-derived adenosine in melanoma.
Soleimani A; Farshchi HK; Mirzavi F; Zamani P; Ghaderi A; Amini Y; Khorrami S; Mashayekhi K; Jaafari MR
Biochimie; 2020 Sep; 176():21-30. PubMed ID: 32585229
[TBL] [Abstract][Full Text] [Related]
36. Small-molecule CD73 inhibitors for the immunotherapy of cancer: a patent and literature review (2017-present).
Nocentini A; Capasso C; Supuran CT
Expert Opin Ther Pat; 2021 Oct; 31(10):867-876. PubMed ID: 33909515
[TBL] [Abstract][Full Text] [Related]
37. Impaired Th1 immunity in ovarian cancer patients is mediated by TNFR2+ Tregs within the tumor microenvironment.
Govindaraj C; Scalzo-Inguanti K; Madondo M; Hallo J; Flanagan K; Quinn M; Plebanski M
Clin Immunol; 2013 Oct; 149(1):97-110. PubMed ID: 23948613
[TBL] [Abstract][Full Text] [Related]
38. CD73: a novel target for cancer immunotherapy.
Zhang B
Cancer Res; 2010 Aug; 70(16):6407-11. PubMed ID: 20682793
[TBL] [Abstract][Full Text] [Related]
39. Blockade of CD73 delays glioblastoma growth by modulating the immune environment.
Azambuja JH; Schuh RS; Michels LR; Iser IC; Beckenkamp LR; Roliano GG; Lenz GS; Scholl JN; Sévigny J; Wink MR; Stefani MA; Battastini AMO; Figueiró F; Teixeira HF; Braganhol E
Cancer Immunol Immunother; 2020 Sep; 69(9):1801-1812. PubMed ID: 32350590
[TBL] [Abstract][Full Text] [Related]
40. Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies.
Antonioli L; Novitskiy SV; Sachsenmeier KF; Fornai M; Blandizzi C; Haskó G
Drug Discov Today; 2017 Nov; 22(11):1686-1696. PubMed ID: 28676406
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
